CRISPR Therapeutics to Present at the American Association for Cancer Research 2023 Annual Meeting
ZUG, Switzerland and BOSTON, March 14, 2023 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical…
ZUG, Switzerland and BOSTON, March 14, 2023 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical…
ZUG, Switzerland and BOSTON, March 13, 2023 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a…
Linea Aspesi Linea Aspesi, Executive Vice President and Chief People Officer, Editas Medicine CAMBRIDGE, Mass.,…
EMERYVILLE, Calif.–(BUSINESS WIRE)–Metagenomi, a genetic medicines company with a versatile portfolio of wholly owned, next-generation…
Reviews 2022 accomplishments; sets forth 2023 milestones and long-term vision LAWRENCEVILLE, N.J., March 01, 2023…
Reviews 2022 accomplishments; sets forth 2023 milestones and long-term vision LAWRENCEVILLE, N.J., March 01, 2023…
LOS ANGELES–(BUSINESS WIRE)–Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm,…
ANAHEIM, CA, Feb. 23, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – BioCorRx Inc. (OTCQB: BICX)…
Initiated the global Phase 2 study of NTLA-2002, a CRISPR-based, potential single-dose treatment for hereditary…
Trem-cel exhibited robust engraftment five months post-transplant through three cycles of Mylotarg Mylotarg treatment enriched…
Trem-cel exhibited robust engraftment five months post-transplant through three cycles of Mylotarg Mylotarg treatment enriched…
Scientists Can Now Begin the mRNA Synthesis Process from Their Own Sequence or Plasmid DNA…
BOSTON, Feb. 16, 2023 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an…
CAMBRIDGE, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage…
New Feature Allows Users to Prioritize Bandwidth for Any Application on the Fly Ensuring Blazing…
WALTHAM, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) — Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company…
~ Revenues of $493.6 million ~ ~ GAAP Diluted Earnings Per Share of $1.86 ~…
SAN DIEGO, Jan. 29, 2023 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today posted…
PALO ALTO, Calif., Jan. 29, 2023 (GLOBE NEWSWIRE) — Scilex Holding Company (Nasdaq: SCLX) announced…
Mr. Langlois Led iSpecimen to 3,000 Percent Revenue Growth During His Tenure as the Company’s…